https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-j9nv9004jjro.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-j9nv9004jjro.html?utm_source=stocktitan-bluesky&utm_medium=social
🧬 Notch Signaling Pathway — The Notch signaling pathway is a conserved metazoan juxtacrine (cell-contact-dependent) signaling mechanism in which both the transmembrane receptors (Notch1–4 in mammals) and their canonical transme…
https://crvscience.com/wiki/notch-signaling-pathway
🧬 Notch Signaling Pathway — The Notch signaling pathway is a conserved metazoan juxtacrine (cell-contact-dependent) signaling mechanism in which both the transmembrane receptors (Notch1–4 in mammals) and their canonical transme…
https://crvscience.com/wiki/notch-signaling-pathway
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
Sign up to read exclusive expert insights on the top data from the meeting! ➡️ www.onclive.com/view/dll3-ta...
Sign up to read exclusive expert insights on the top data from the meeting! ➡️ www.onclive.com/view/dll3-ta...
Read more! https://bit.ly/4sTbJmc
Read more! https://bit.ly/4sTbJmc
Learn more: https://bit.ly/4sCx9Ux
Learn more: https://bit.ly/4sCx9Ux
prismmarketview.com/allogene-to-...
prismmarketview.com/allogene-to-...
This study identifies DLL3 as a driver of #tumor progression and T-cell exhaustion in neuroendocrine cervical carcinoma, revealing a promising therapeutic target. @fudanuni_official
#GenesAndDiseases: doi.org/10.1016/j.ge...
This study identifies DLL3 as a driver of #tumor progression and T-cell exhaustion in neuroendocrine cervical carcinoma, revealing a promising therapeutic target. @fudanuni_official
#GenesAndDiseases: doi.org/10.1016/j.ge...
pharmaphorum.com/news/esmo26-...
pharmaphorum.com/news/esmo26-...
pharmaphorum.com/news/esmo26-...
pharmaphorum.com/news/esmo26-...
Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones
#SEC #stocks #investing #ZYME #Mergers
🔗 secwatch.observer
Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones
#SEC #stocks #investing #ZYME #Mergers
🔗 secwatch.observer
📅 October 23 | 3:15 p.m. CEST
📅 October 23 | 3:15 p.m. CEST
https://www.stocktitan.net/news/IDYA/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-mb8r58o67ka9.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IDYA/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-mb8r58o67ka9.html?utm_source=stocktitan-bluesky&utm_medium=social
さらに、セロトニン産生を抑えるとがん免疫療法の効果が高まった in mice.
肺神経内分泌がんがセロトニンを利用して抗腫瘍免疫応答を抑える仕組みを解明―免疫療法への治療抵抗性の克服につながることが期待―
pod.ncc.go.jp/jp/informati...
さらに、セロトニン産生を抑えるとがん免疫療法の効果が高まった in mice.
肺神経内分泌がんがセロトニンを利用して抗腫瘍免疫応答を抑える仕組みを解明―免疫療法への治療抵抗性の克服につながることが期待―
pod.ncc.go.jp/jp/informati...
https://www.merlintrader.com/ideaya-biosciences-stock-hub/
https://www.merlintrader.com/ideaya-biosciences-stock-hub/
https://www.merlintrader.com/zymeworks-stock-hub/
https://www.merlintrader.com/zymeworks-stock-hub/
https://www.stocktitan.net/news/ZYME/zymeworks-enters-into-an-exclusive-global-license-and-collaboration-gb7vljiv6iqp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ZYME/zymeworks-enters-into-an-exclusive-global-license-and-collaboration-gb7vljiv6iqp.html?utm_source=stocktitan-bluesky&utm_medium=social